GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clal Biotechnology Industries Ltd (XTAE:CBI) » Definitions » Other Income (Expense)

Clal Biotechnology Industries (XTAE:CBI) Other Income (Expense) : ₪75.45 Mil (TTM As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Clal Biotechnology Industries Other Income (Expense)?

Clal Biotechnology Industries's other income expense for the Clal Biotechnology Industries's pretax income for the three months ended in Dec. 2023 was ₪0.00 Mil. Its other income expense for the trailing twelve months (TTM) ended in Dec. 2023 was ₪75.45 Mil.


Clal Biotechnology Industries Other Income (Expense) Historical Data

The historical data trend for Clal Biotechnology Industries's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clal Biotechnology Industries Other Income (Expense) Chart

Clal Biotechnology Industries Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Income (Expense)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -331.35 182.34 155.61 59.57 93.39

Clal Biotechnology Industries Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Dec23
Other Income (Expense) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -25.47 -10.58 86.02 - -

Clal Biotechnology Industries Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₪75.45 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Clal Biotechnology Industries  (XTAE:CBI) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.


Clal Biotechnology Industries (XTAE:CBI) Business Description

Traded in Other Exchanges
N/A
Address
Azrieli Center, Triangle Building, 45th Floor, Tel Aviv, ISR, 67023
Clal Biotechnology Industries Ltd is a life sciences investment company. The company invests in companies ranging from seed to maturity, both public and private. Its portfolio of investments includes from heavy industry to biotechnology, hi-tech and energy companies.

Clal Biotechnology Industries (XTAE:CBI) Headlines

From GuruFocus

CB&I Announces Storage Award for Export Facility in Canada

By PRNewswire PRNewswire 04-26-2018

Does the Increase in Volatility Signal a Dangerous Market Environment?

By Chuck Carnevale Chuck Carnevale 11-11-2016

This Warren Buffett Bargain Stock Is Good For A Double

By Jonathan Poland Jonathan Poland 05-27-2015

Richard Snow Increases His Stake in Chicago Bridge and Iron

By Ashish Sharma Lalitsharma 09-14-2015

McDermott Awarded Paraxylene (pX) Technology Contract in China

By PRNewswire PRNewswire 06-13-2019

CB&I Announces DPC Technology Award in China

By PRNewswire PRNewswire 04-03-2018

CB&I Announces Novolen Technology Award in China

By PRNewswire PRNewswire 04-03-2018